Interestingly, recent research has revealed that the activation of NRF2, achieved by inhibiting KEAP1, can reduce the viability of several lung cancer cell lines, suggesting that high NRF2 activity may lead to cell death and sensitize cancer cells to chemotherapeutic agents [128]. This evidence concerns the gene NFE2L2 and cancer.